XML 42 R74.htm IDEA: XBRL DOCUMENT v3.19.3
Lines of Credit and Long-Term Debt - Long-Term Debt - Additional Information (Details)
1 Months Ended 3 Months Ended 9 Months Ended
Dec. 31, 2018
USD ($)
Sep. 30, 2018
USD ($)
Jul. 31, 2018
USD ($)
day
$ / shares
Sep. 30, 2019
USD ($)
Sep. 30, 2018
USD ($)
Sep. 30, 2019
USD ($)
Sep. 30, 2018
USD ($)
Debt Instrument [Line Items]              
Long-term debt divested from deconsolidation       $ 4,030,000   $ 4,030,000  
Proceeds from long-term debt, net of issuance costs           376,000 $ 194,000,000
Equity component of convertible debt, net of issuance costs and deferred taxes         $ 36,868,000   36,868,000
Deferred income taxes       467,000 14,246,000 1,448,000 19,335,000
Accrued interest       1,750,000   1,750,000  
Long-term debt issued to a related party in an asset acquisition           0 30,000,000
Interest expense       4,471,000 $ 3,999,000 13,140,000 $ 4,240,000
Long-term debt $ 211,794,000     215,467,000   215,467,000  
Convertible debt              
Debt Instrument [Line Items]              
Long-term debt 203,391,000     211,037,000   211,037,000  
Notes payable              
Debt Instrument [Line Items]              
Long-term debt 4,551,000     4,204,000   4,204,000  
ActoBio Therapeutics Inc. | Convertible debt | Harvest Intrexon Enterprise Fund I, LP              
Debt Instrument [Line Items]              
Debt instrument, interest rate, stated percentage   3.00%     3.00%   3.00%
Interest expense       232,000 $ 60,000 684,000 $ 60,000
Long-term debt       $ 30,974,000   $ 30,974,000  
Trans Ova Genetics, LC | Notes payable | American State Bank              
Debt Instrument [Line Items]              
Debt instrument, interest rate, stated percentage       3.95%   3.95%  
Long-term debt       $ 4,180,000   $ 4,180,000  
Debt instrument, periodic payment           39,000  
Harvest Intrexon Enterprise Fund I, LP | ActoBio Therapeutics Inc.              
Debt Instrument [Line Items]              
Long-term debt issued to a related party in an asset acquisition   $ 30,000,000          
3.5% Convertible Notes Due 2023              
Debt Instrument [Line Items]              
Aggregate principal amount     $ 200,000,000 $ 200,000,000   $ 200,000,000  
Proceeds from long-term debt, net of issuance costs     193,958,000        
Debt issuance costs     $ 6,042,000        
Debt instrument, interest rate, stated percentage     3.50% 3.50%   3.50%  
Conversion rate     58.6622        
Principal amount used in conversion     $ 1,000        
Conversion price (in usd per share) | $ / shares     $ 17.05        
Debt instrument redemption price, percentage     100.00%        
Carrying value of convertible debt 148,101,000   $ 143,723,000 $ 155,063,000   $ 155,063,000  
Equity component of convertible debt, net of issuance costs and deferred taxes     50,235,000        
Deferred income taxes     $ 13,367,000   $ 13,367,000    
Effective interest rate on convertible notes       11.02%   11.02%  
Convertible notes, unamortized discount and issuance costs       $ 44,937,000   $ 44,937,000  
3.5% Convertible Notes Due 2023 | Minimum              
Debt Instrument [Line Items]              
Common stock price trading days | day     20        
Common stock price consecutive trading days | day     30        
Percentage of common share price over conversion price for conversion     130.00%        
3.5% Convertible Notes Due 2023 | Maximum              
Debt Instrument [Line Items]              
Common stock price trading days | day     5        
Common stock price consecutive trading days | day     5        
Debt instrument redemption price, percentage     98.00%        
Merck Convertible Note              
Debt Instrument [Line Items]              
Aggregate principal amount $ 25,000,000            
Conversion rate upon IPO 0.90            
Interest rate applicable to IPO conversion event 0.05